{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:12:53Z","timestamp":1770433973751,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T00:00:00Z","timestamp":1173744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p><jats:bold>Objective\u2002<\/jats:bold> To assess the tolerability and efficacy of duloxetine in a nontrial situation.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Prospective observational study.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Urogynaecology Unit, District General Hospital, UK.<\/jats:p><jats:p><jats:bold>Population\u2002<\/jats:bold> Two hundred and twenty\u2010two women with a diagnosis of urodynamic stress incontinence (USI) or mixed USI and detrusor overactivity (DOA) took duloxetine for 4 weeks.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The results of therapy were assessed with a Patient Global Impression of Improvement (PGI\u2010I) questionnaire. One hundred and forty\u2010eight (67%) women were initially treated with 40 mg twice a day, 67 (30%) women were treated with an escalating dose initially at 20 mg twice a day increasing to 40 mg twice a day after 2 weeks and seven (3%) women were started on a dose of 20 mg twice a day which they continued.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> Discontinuation rates and PGI\u2010I scores.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Overall 146\/222 (66%) women discontinued therapy due to adverse effects or lack of efficacy. Significantly more women starting on the 40 mg twice a day dose stopped due to adverse effects when compared with the escalating dose (<jats:italic>P<\/jats:italic> &lt; 0.025). Of the women who tolerated therapy, 80 out of 120 (67%) had a PGI\u2010I score indicating an improvement. However, the overall rate of improvement was 37%. PGI\u2010I scores and discontinuation rates were not significantly different between the group with USI and the group with mixed USI and DOA (<jats:italic>P<\/jats:italic> &gt; 0.05).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> In a nontrial situation duloxetine is poorly tolerated. Introducing an escalating dose may improve tolerability. A similar number of women with USI and mixed incontinence had a PGI\u2010I score indicating improvement.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2007.01288.x","type":"journal-article","created":{"date-parts":[[2007,3,13]],"date-time":"2007-03-13T07:23:24Z","timestamp":1173770604000},"page":"543-547","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Tolerability and efficacy of duloxetine in a nontrial situation"],"prefix":"10.1111","volume":"114","author":[{"given":"JRA","family":"Duckett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Vella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Kavalakuntla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(03)00220-0"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1464-410X.2003.04609.x","article-title":"The prevalence of urinary incontinence in women in four European countries","volume":"93","author":"Hunsakar S","year":"2004","journal-title":"BJU Int"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb11006.x"},{"key":"e_1_2_5_6_2","first-page":"1589","volume-title":"Incontinence","author":"Abrams P","year":"2005"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000080708.87092.cc"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04607.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.124840"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00067.x"},{"key":"e_1_2_5_11_2","first-page":"809","volume-title":"Incontinence","author":"Andersson KE","year":"2005"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00192-005-0063-9","article-title":"Duloxetine treatment for women awaiting continence surgery","volume":"17","author":"Duckett JR","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(03)00376-4"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000134525.86480.0f"},{"key":"e_1_2_5_15_2","first-page":"582","article-title":"The effect of duloxetine dose escalating and tapering on the incidence of adverse events in women with stress urinary incontinence","volume":"24","author":"Bump R","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7496.895"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","unstructured":"MariappanP BallantyneZ N\u2019DowJMO AlhassoAA.Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults (Review).2006[http:\/\/www.thecochranelibrary.com]. Accessed 25 May 2005.","DOI":"10.1002\/14651858.CD004742.pub2"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2007.01288.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2007.01288.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:32:09Z","timestamp":1697380329000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2007.01288.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,11]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1471-0528.2007.01288.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2007.01288.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,11]]},"assertion":[{"value":"2007-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}